Home | Business News | Browse by Publication | P | Pharma Marketletter

AG-1067 misses Ph III primary endpoint; AstraZeneca may drop AtheroGenics accord.

Publication: Pharma Marketletter
Publication Date: 26-MAR-07
Format: Online
Delivery: Immediate Online Access
Full Article Title: AG-1067 misses Ph III primary endpoint; AstraZeneca may drop AtheroGenics accord.(Brief article)

Article Excerpt
US drugmaker AtheroGenics says that a Phase III, 6,000-patient clinical study of its lead drug candidate, AGI-1067, did not show a difference from placebo in a composite primary endpoint of reduction in risk of death, heart attack or stroke in patients with coronary artery disease.

The anti-inflammatory and anti-oxidant drug, which is the subject of a $1.0 billion licensing agreement with the UK's second-largest drugmaker, AstraZeneca (Marketletter January 9, 2006), failed to reduce a composite of "hard" atherosclerotic clinical endpoints, and also did not improve several key diabetes parameters, including glycemic control....

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!



More articles from Pharma Marketletter
Isis antisense drug cutsl atherogenic ipids.(Brief article), April 02, 2007
Torcetrapib does not slow plaque build-up.(Brief article), April 02, 2007
Czech patient records.(Brief article), April 02, 2007
Innogenetics NV raises 31.7M euros via convertible bond issue.(Brief a..., April 02, 2007
bioMerieux and Copan in technology licensing deal.(Brief article), April 02, 2007

Looking for additional articles?
Search our database of over 3 million articles.

Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication name or publication date.

About Goliath
Whether you're looking for sales prospects, competitive information, company analysis or best practices in managing your organization, Goliath can help you meet your business needs.

Our extensive business information databases empower business professionals with both the breadth and depth of credible, authoritative information they need to support their business goals. Whether it be strategic planning, sales prospecting, company research or defining management best practices - Goliath is your leading source for accurate information.